SK Biopharmaceuticals and SK Chemicals, both part of the SK Group, have signed a co-development agreement for YKP10811 to treat irritable bowel syndrome with constipation (IBS-C). Under the deal, SK Chemicals will carry out later-stage ...
SK Biopharmaceuticals has signed a licensing agreement with Hanmi Pharmacutical for diazepam nasal spray (DZNS) technology. Under the terms of the agreement, Hanmi acquired regional marketing rights for Korea and China and will make an ...
Tags: Hanmi for Dzns Technology, Medicine, Pharmacutical Hanmi
SK Biopharmaceuticals, a South Korean pharmaceutical company, has received orphan drug designation status for carisbamate for the management of patients with infantile spasms (IS). Carisbamate has previously been shown to have ...